

Chapter 34

REFERENCES

1. Naguib M, Flood P, McArdle JJ, et al. Advances in neurobiology of the neuromuscular junction: implications for the anesthesiologist. *Anesthesiology*. 2002;96:202.
2. Katz RL. Neuromuscular effects of d-tubocurarine, edrophonium and neostigmine in man. *Anesthesiology*. 1967;28:327.
3. Martyn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states. Etiologic factors and molecular mechanisms. *Anesthesiology*. 2006;104:158.
4. Ali HH, Savarese JJ. Monitoring of neuromuscular blockade. *Anesthesiology*. 1976;45:216.
5. Ali HH, Savarese JJ. Stimulus frequency and dose-response curve to d-tubocurarine in man. *Anesthesiology*. 1980;52:36.
6. Ali HH, Savarese JJ, Lebowitz PW, et al. Twitch, tetanus and train-of-four as indices of recovery from nondepolarizing neuromuscular blockade. *Anesthesiology*. 1981;54:294.
7. Ali HH, Utting JE, Gray TC. Quantitative assessment of residual antidepolarizing block. I. *Br J Anaesth*. 1971;43:473.
8. Ali HH, Utting JE, Gray TC. Quantitative assessment of residual antidepolarizing block. II. *Br J Anaesth*. 1971;43:478.
9. Ali HH. Criteria of adequate clinical recovery from neuromuscular block. *Anesthesiology*. 2003;98:1278.
10. Viby-Mogensen J, Howardy-Hansen P, Chraemmer-Jorgensen B, et al. Posttetanic count (PTC): a new method of evaluating an intense nondepolarizing neuromuscular blockade. *Anesthesiology*. 1981;55:458.
11. Drenck NE, Ueda N, Olsen NV, et al. Manual evaluation of residual curarization using double burst stimulation: a comparison with train-of-four. *Anesthesiology*. 1989;70:578.
12. Engbaek J, Ostergaard D, Viby-Mogensen J. Double burst stimulation (DBS): a new pattern of nerve stimulation to identify residual neuromuscular block. *Br J Anaesth*. 1989;62:274.
13. Pino R, Ali HH. Monitoring neuromuscular blockade. *Curr Opin Anesthesiol*. 1995;8:348.
14. Eikermann M, Groeben H, Husing J, et al. Accelerometry of adductor pollicis muscle predicts recovery of respiratory function from neuromuscular blockade. *Anesthesiology*. 2003;98:1333.
15. Viby-Mogensen J, Jensen NH, Engbaek J, et al. Tactile and visual evaluation of the response to train-of-four nerve stimulation. *Anesthesiology*. 1985;63:440.
16. Bartkowski RR, Witkowski TA, Azad S, et al. Rocuronium onset of action: a comparison with atracurium and vecuronium. *Anesth Analg*. 1993;77:574.
17. Kopman AF. Pancuronium, gallamine, and d-tubocurarine compared: is speed of onset inversely related to drug potency? *Anesthesiology*. 1989;70:915.
18. Donati F, Meistelman C, Plaud B. Vecuronium neuromuscular blockade at the adductor muscles of the larynx and adductor pollicis. *Anesthesiology*. 1991;74:833.
19. Donati F, Meistelman C, Plaud B. Vecuronium neuromuscular blockade at the diaphragm, the orbicularis oculi, and adductor pollicis muscles. *Anesthesiology*. 1990;73:870.
20. Mehta MP, Choi WW, Gergis SD, et al. Facilitation of rapid endotracheal intubations with divided doses of nondepolarizing neuromuscular blocking drugs. *Anesthesiology*. 1985;62:392.
21. Ali HH, Lien CA, Witkowski T, et al. Efficacy and safety of divided dose administration of mivacurium for a 90-second tracheal intubation. *J Clin Anesth*. 1996;8:276.
22. Pino RM, Ali HH, Denman WT, et al. A comparison of the intubation conditions between mivacurium and rocuronium during balanced anesthesia. *Anesthesiology*. 1998;88:673.
23. Miller RD. The priming principle. *Anesthesiology*. 1985;62:381.
24. Mak PH, Irwin MG. The effect of cisatracurium and rocuronium on cisatracurium precurarization and the priming principle. *J Clin Anesth*. 2004;16:83.
25. Naguib M, Abdulatif M, Gyasi HK, et al. Priming with atracurium: improving intubating conditions with additional doses of thiopental. *Anesth Analg*. 1986;65:1295.
26. Schwarz S, Ilias W, Lackner F, et al. Rapid tracheal intubation with vecuronium: the priming principle. *Anesthesiology*. 1985;62:388.
27. Taboada JA, Rupp SM, Miller RD. Refining the priming principle for vecuronium during rapid-sequence induction of anesthesia. *Anesthesiology*. 1986;64:243.
28. Naguib M, Samarkandi AH, Abdullah K, et al. Succinylcholine dosage and apnea-induced hemoglobin desaturation in patients. *Anesthesiology*. 2005;102:35.
29. Levano S, Ginz H, Siegemund M, et al. Genotyping the butyrylcholinesterase in patients with prolonged neuromuscular block after succinylcholine. *Anesthesiology*. 2005;102:531.
30. Whittaker M. Plasma cholinesterase variants and the anaesthetist. *Anaesthesia*. 1980;35:174.
31. Schow AJ, Lubarsky DA, Olson RP, et al. Can succinylcholine be used safely in hyperkalemic patients? *Anesth Analg*. 2002;95:119.

32. Donlon JV. Succinylcholine and open eye injuries. *Anesthesiology*. 1986;65:526.
33. Libonati M, Leahy J, Ellson V. The use of succinylcholine in open eye surgery. *Anesthesiology*. 1986;64:517.
34. Vachon CA, Warner DO, Bacon DR. Succinylcholine and the open globe. Tracing the teaching. *Anesthesiology*. 2003;99:220.
35. Savarese JJ, Ali HH, Basta SJ, et al. The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U). A short-acting nondepolarizing ester neuromuscular blocking drug. *Anesthesiology*. 1988;68:723.
36. Basta SJ. Clinical pharmacology of mivacurium chloride: a review. *J Clin Anesth*. 1992;4:153.
37. Savarese JJ, Ali HH, Basta SJ, et al. The cardiovascular effects of mivacurium chloride (BW B1090U) in patients receiving nitrous oxide-opiate-barbiturate anesthesia. *Anesthesiology*. 1989;70:386.
38. Cook DR, Stiller RL, Weakly JN, et al. In vitro metabolism of mivacurium chloride (BW B1090U) and succinylcholine. *Anesth Analg*. 1989;68:452.
39. Gatke MR, Viby-Mogensen J, Ostergaard D, et al. Response to mivacurium in patients carrying the k variant in the butyrylcholinesterase gene. *Anesthesiology*. 2005;102:503.
40. Ali HH, Savarese JJ, Embree PB, et al. Clinical pharmacology of mivacurium chloride (BW B1090U) infusion: comparison with vecuronium and atracurium. *Br J Anaesth*. 1988;61:541.
41. Caldwell JE, Heier T, Kitts JB, et al. Comparison of the neuromuscular block induced by mivacurium, suxamethonium or atracurium during nitrous oxide-fentanyl anaesthesia. *Br J Anaesth*. 1989;63:393.
42. Basta SJ, Ali HH, Savarese JJ, et al. Clinical pharmacology of atracurium besylate (BW 33A): a new non-depolarizing muscle relaxant. *Anesth Analg*. 1982;61:723.
43. Hughes R, Chapple DJ. The pharmacology of atracurium: a new competitive neuromuscular blocking agent. *Br J Anaesth*. 1981;53:31.
44. Lien CA, Schmith VD, Belmont MR, et al. Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. *Anesthesiology*. 1996;84:300.
45. Fisher DM, Canfell PC, Spellman MJ, et al. Pharmacokinetics and pharmacodynamics of atracurium in infants and children. *Anesthesiology*. 1990;73:33.
46. Ward S, Neill EA, Weatherley BC, et al. Pharmacokinetics of atracurium besylate in healthy patients (after a single i.v. bolus dose). *Br J Anaesth*. 1983;55:113.
47. Fahey MR, Rupp SM, Fisher DM, et al. The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. *Anesthesiology*. 1984;61:699.
48. Brandom BW, Stiller RL, Cook DR, et al. Pharmacokinetics of atracurium in anaesthetized infants and children. *Br J Anaesth*. 1986;58:1210.
49. Kent AP, Parker CJ, Hunter JM. Pharmacokinetics of atracurium and laudanosine in the elderly. *Br J Anaesth*. 1989;63:661.
50. d'Hollander AA, Luyckx C, Barvais L, et al. Clinical evaluation of atracurium besylate requirement for a stable muscle relaxation during surgery: lack of age-related effects. *Anesthesiology*. 1983;59:237.
51. Scott RP, Savarese JJ, Basta SJ, et al. Atracurium: clinical strategies for preventing histamine release and attenuating the haemodynamic response. *Br J Anaesth*. 1985;57:550.
52. Savage DS, Sleigh T, Carlyle I. The emergence of ORG NC 45, 1-[2 beta,3 alpha,5 alpha,16 beta,17 beta]-3, 17-bis(acetyloxy)-2-(1-piperidinyl)-androstan-16-yl]-1-methylpiperidinium bromide, from the pancuronium series. *Br J Anaesth*. 1980;52 (Suppl 1):3S.
53. Fahey MR, Morris RB, Miller RD, et al. Clinical pharmacology of ORG NC45 (Norcuron™): a new nondepolarizing muscle relaxant. *Anesthesiology*. 1981;55:6.
54. Duvaldestin P, Saada J, Berger JL, et al. Pharmacokinetics, pharmacodynamics, and dose-response relationships of pancuronium in control and elderly subjects. *Anesthesiology*. 1982;56:36.
55. Marshall IG, Gibb AJ, Durant NN. Neuromuscular and vagal blocking actions of pancuronium bromide, its metabolites, and vecuronium bromide (Org NC45) and its potential metabolites in the anaesthetized cat. *Br J Anaesth*. 1983;55:703.
56. d'Hollander A, Massaux F, Nevelsteen M, et al. Age-dependent dose-response relationship of ORG NC 45 in anaesthetized patients. *Br J Anaesth*. 1982;54:653.
57. Segredo V, Caldwell JE, Matthey MA, et al. Persistent paralysis in critically ill patients after long-term administration of vecuronium. *N Engl J Med*. 1992;327:524.
58. Fisher DM, Castagnoli K, Miller RD. Vecuronium kinetics and dynamics in anesthetized infants and children. *Clin Pharmacol Ther*. 1985;37:402.
59. Morris RB, Cahalan MK, Miller RD, et al. The cardiovascular effects of vecuronium (ORG NC45) and pancuronium in patients undergoing coronary artery bypass grafting. *Anesthesiology*. 1983;58:438.
60. Futo J, Kupferberg JP, Moss J. Inhibition of histamine N-methyltransferase (HNMT) in vitro by neuromuscular relaxants. *Biochem Pharmacol*. 1990;39:415.
61. Durrani Z, O'Hara J. Histaminoid reaction from vecuronium priming: a case report. *Anesthesiology*. 1987;67:130.
62. Lavery GG, Hewitt AJ, Kenny NT. Possible histamine release after vecuronium. *Anaesthesia*. 1985;40:389.
63. Mayer M, Doenicke A, Hofmann A, et al. Onset and recovery of rocuronium (Org 9426) and vecuronium under enflurane anaesthesia. *Br J Anaesth*. 1992;69:511.
64. Khuenl-Brady KS, Pomaroli A, Puhlinger F, et al. The use of rocuronium (ORG 9426) in patients with chronic renal failure. *Anaesthesia*. 1993;48:873.
65. Szenohradszky J, Fisher DM, Segredo V, et al. Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. *Anesthesiology*. 1992;77:899.
66. Khalil M, D'Honneur G, Duvaldestin P, et al. Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. *Anesthesiology*. 1994;80:1241.
67. Matteo RS, Ornstein E, Schwartz AE, et al. Pharmacokinetics and pharmacodynamics of rocuronium (Org 9426) in elderly surgical patients. *Anesth Analg*. 1993;77:1193.
68. McCoy EP, Maddineni VR, Elliott P, et al. Haemodynamic effects of rocuronium during fentanyl anaesthesia: comparison with vecuronium. *Can J Anaesth*. 1993;40:703.
69. Magorian T, Flannery KB, Miller RD. Comparison of rocuronium, succinylcholine, and vecuronium for rapid-sequence induction of anesthesia in adult patients. *Anesthesiology*. 1993;79:913.

70. Khuenl-Brady K, Castagnoli KP, Canfell PC, et al. The neuromuscular blocking effects and pharmacokinetics of ORG 9426 and ORG 9616 in the cat. *Anesthesiology*. 1990;72:669.
71. Duvaldestin P, Agoston S, Henzel D, et al. Pancuronium pharmacokinetics in patients with liver cirrhosis. *Br J Anaesth*. 1978;50:1131.
72. Ramsey FM, Lebowitz PW, Savarese JJ, et al. Clinical characteristics of long-term succinylcholine neuromuscular blockade during balanced anesthesia. *Anesth Analg*. 1980;59:110.
73. Shanks CA, Fragen RJ, Ling D. Continuous intravenous infusion of rocuronium (ORG 9426) in patients receiving balanced, enflurane, or isoflurane anesthesia. *Anesthesiology*. 1993;78:649.
74. Miller DR, Wherrett C, Hull K, et al. Cumulation characteristics of cisatracurium and rocuronium during continuous infusion. *Can J Anaesth*. 2000;47:943.
75. Pino RM. Neuromuscular blockade studies of critically ill patients. *Intensive Care Med*. 2002;28:1695.
76. Papazian L, Forel J-M, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. *N Engl J Med*. 2010;363:1007.
77. Slutsky AS. Neuromuscular blocking agents in ARDS. *N Engl J Med*. 2010;363:1176.
78. de Jonghe B, Lacherade J-C, Sharshar T, et al. Intensive care unit-acquired weakness: risk factors and prevention. *Crit Care Med*. 2009;37(Suppl):S309-S315.
79. Hansen-Flaschen J, Cowen J, Raps EC. Neuromuscular blockade in the intensive care unit. More than we bargained for. *Am Rev Respir Dis*. 1993;147:234.
80. Watling SM, Dasta JF. Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: a review of the literature. *Crit Care Med*. 1994;22:884.
81. Gooch JL, Suchyta MR, Balbierz JM, et al. Prolonged paralysis after treatment with neuromuscular junction blocking agents. *Crit Care Med*. 1991;19:1125.
82. Giostra E, Magistris MR, Pizzolato G, et al. Neuromuscular disorder in intensive care unit patients treated with pancuronium bromide. Occurrence in a cluster group of seven patients and two sporadic cases, with electrophysiologic and histologic examination. *Chest*. 1994;106:210.
83. Prielipp RC, Coursin DB, Scuderi PE, et al. Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients. *Anesth Analg*. 1995;81:3.
84. Chapple DJ, Miller AA, Ward JB, et al. Cardiovascular and neurological effects of laudanosine. Studies in mice and rats, and in conscious and anesthetized dogs. *Br J Anaesth*. 1987;59:218.
85. Debaene B, Plaud B, Dilly MP, et al. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. *Anesthesiology*. 2003;98:1042.
86. Hayes AH, Mirakhur RK, Breslin DS, et al. Postoperative residual block after intermediate-acting neuromuscular blocking drugs. *Anaesthesia*. 2001;56:312.
87. Murphy GS, Szokol JW, Franklin M, et al. Postanesthesia care unit recovery times and neuromuscular blocking drugs: a prospective study of orthopedic surgical patients randomized to receive pancuronium or rocuronium. *Anesth Analg*. 2004;98:193.
88. Pino RM. Residual neuromuscular blockade: a persistent clinical problem. *Int Anesthesiol Clin*. 2006;44:77.
89. Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. *Anesth Analg*. 2010;111:120.
90. Brull SJ, Murphy GS. Residual neuromuscular block: lessons unlearned. Part II: methods to reduce the risk of residual weakness. *Anesth Analg*. 2010;111:129.
91. Eriksson LI, Sundman E, Olsson R, et al. Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans: simultaneous videomanometry and mechanomyography of awake human volunteers. *Anesthesiology*. 1997;87:1035.
92. Kirkegaard H, Heier T, Caldwell JE. Efficacy of tactile-guided reversal from cisatracurium-induced neuromuscular block. *Anesthesiology*. 2002;96:45.
93. Eikermann M, Blobner MM, Groeben H, et al. Postoperative upper airway obstruction after recovery of the train of four ratio of the adductor pollicis muscle from neuromuscular blockade. *Anesth Analg*. 2006;102:937.
94. Maybauer DM, Geldner G, Blobner M, et al. Incidence and duration of residual paralysis at the end of surgery after multiple administrations of cisatracurium and rocuronium. *Anesthesia*. 2007;62:12.
95. Kopman AF, Chin WA, Moe J. Dose-response relationship of rocuronium: a comparison of electromyographic vs. acceleromyographic-derived values. *Acta Anaesthesiol Scand*. 2005;49:323.
96. Magorian TT, Lynam DP, Caldwell JE, et al. Can early administration of neostigmine, in single or repeated doses, alter the course of neuromuscular recovery from a vecuronium-induced neuromuscular blockade? *Anesthesiology*. 1990;73:410.
97. Sacan O, White PF, Tufanogullari B, et al. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. *Anesth Analg*. 2007;104:569.
98. de Boer HD, van Egmond J, van de Pol F, et al. Reversal of profound rocuronium neuromuscular blockade by sugammadex in anesthetized rhesus monkeys. *Anesthesiology*. 2006;104:718.
99. Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. *Anesthesiology*. 2006;104:667.
100. Suy K, Morias K, Cammu G, et al. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex; a selective relaxant binding agent. *Anesthesiology*. 2007;106:283.
101. Savarese JJ, McGilvra JD, Sunaga H, et al. Rapid chemical antagonism of neuromuscular blockade by L-cysteine adduction to and inactivation of the olefinic (double-bonded) isoquinolinium diester compounds gantacurium (AV430A), CW 002, and CW 011. *Anesthesiology*. 2010;113:58.